Literature DB >> 30242614

Morphine Potentiates Dysbiotic Microbial and Metabolic Shifts in Acute SIV Infection.

Gregory M Sindberg1, Shannon E Callen2, Santanu Banerjee3,4, Jingjing Meng3,4, Vanessa L Hale5, Ramakrishna Hegde6, Paul D Cheney6, Francois Villinger7, Sabita Roy8,9,10, Shilpa Buch11.   

Abstract

Human Immunodeficiency Virus (HIV) pathogenesis has been closely linked with microbial translocation, which is believed to drive inflammation and HIV replication. Opioid drugs have been shown to worsen this symptom, leading to a faster progression of HIV infection to Acquired Immunodeficiency Syndrome (AIDS). The interaction of HIV and opioid drugs has not been studied at early stages of HIV, particularly in the gut microbiome where changes may precede translocation events. This study modeled early HIV infection by examining Simian Immunodeficiency Virus (SIV)-infected primates at 21 days or less both independently and in the context of opioid use. Fecal samples were analyzed both for 16S analysis of microbial populations as well as metabolite profiles via mass spectrometry. Our results indicate that changes are minor in SIV treated animals in the time points examined, however animals treated with morphine and SIV had significant changes in their microbial communities and metabolic profiles. This occurred in a time-independent fashion with morphine regardless of how long the animal had morphine in its system. Globally, the observed changes support that microbial dysbiosis is occurring in these animals at an early time, which likely contributes to the translocation events observed later in SIV/HIV pathogenesis. Additionally, metabolic changes were predictive of specific treatment groups, which could be further developed as a diagnostic tool or future intervention target to overcome and slow the progression of HIV infection to AIDS.

Entities:  

Keywords:  HIV pathogenesis; Intestine metabolism; Intestine microbiome; Non-human primates; Opioids; SIV

Year:  2018        PMID: 30242614      PMCID: PMC6917429          DOI: 10.1007/s11481-018-9805-6

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  76 in total

1.  Morphine induces CD4+ T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway.

Authors:  Sabita Roy; Jinghua Wang; Richard Charboneau; Horace H Loh; Roderick A Barke
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

2.  Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro.

Authors:  J A Gurwell; A Nath; Q Sun; J Zhang; K M Martin; Y Chen; K F Hauser
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

3.  Relationship between enteric microecologic dysbiosis and bacterial translocation in acute necrotizing pancreatitis.

Authors:  Cheng-Tang Wu; Zhan-Liang Li; De-Xin Xiong
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

4.  Morphological correlates of neurological dysfunction in macaques infected with neurovirulent simian immunodeficiency virus.

Authors:  R Raghavan; P D Cheney; L A Raymond; S V Joag; E B Stephens; I Adany; D M Pinson; Z Li; J K Marcario; F Jia; C Wang; L Foresman; N E Berman; O Narayan
Journal:  Neuropathol Appl Neurobiol       Date:  1999-08       Impact factor: 8.090

Review 5.  Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.

Authors:  M D Gershon
Journal:  Aliment Pharmacol Ther       Date:  2004-11       Impact factor: 8.171

6.  Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats.

Authors:  Vicente Lorenzo-Zúñiga; Ramón Bartolí; Ramón Planas; Alan F Hofmann; Belén Viñado; Lee R Hagey; José M Hernández; Josep Mañé; Marco A Alvarez; Vicente Ausina; Miquel Angel Gassull
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

7.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways.

Authors:  Jinghua Wang; Roderick A Barke; Richard Charboneau; Horace H Loh; Sabita Roy
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

10.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

View more
  8 in total

1.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 2.  Opioid Use, Gut Dysbiosis, Inflammation, and the Nervous System.

Authors:  Richa Jalodia; Yaa Fosuah Abu; Mark Ryan Oppenheimer; Bridget Herlihy; Jingjing Meng; Irina Chupikova; Junyi Tao; Nillu Ghosh; Rajib Kumar Dutta; Udhghatri Kolli; Yan Yan; Eridania Valdes; Madhulika Sharma; Umakant Sharma; Shamsudheen Moidunny; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-07       Impact factor: 4.147

Review 3.  Contributions of neuroimmune and gut-brain signaling to vulnerability of developing substance use disorders.

Authors:  Kelsey E Lucerne; Aya Osman; Katherine R Meckel; Drew D Kiraly
Journal:  Neuropharmacology       Date:  2021-05-06       Impact factor: 5.273

4.  The role of gut-immune-brain signaling in substance use disorders.

Authors:  Kelsey E Lucerne; Drew D Kiraly
Journal:  Int Rev Neurobiol       Date:  2020-10-24       Impact factor: 4.280

Review 5.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

Review 6.  Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders.

Authors:  Sierra Simpson; Rio Mclellan; Emma Wellmeyer; Frederic Matalon; Olivier George
Journal:  J Neuroimmune Pharmacol       Date:  2021-10-25       Impact factor: 7.285

Review 7.  Drugs of Abuse and Their Impact on Viral Pathogenesis.

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Viruses       Date:  2021-11-29       Impact factor: 5.048

Review 8.  On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance.

Authors:  Susanna Fürst; Zoltán S Zádori; Ferenc Zádor; Kornél Király; Mihály Balogh; Szilvia B László; Barbara Hutka; Amir Mohammadzadeh; Chiara Calabrese; Anna Rita Galambos; Pál Riba; Patrizia Romualdi; Sándor Benyhe; Júlia Timár; Helmut Schmidhammer; Mariana Spetea; Mahmoud Al-Khrasani
Journal:  Molecules       Date:  2020-05-26       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.